Why Agilent Is Spending up to $270 Million on an AI Pathology Specialist
Agilent (A) to acquire Proscia for up to $270M to expand AI-powered digital pathology & diagnostic capabilities. Stock edges higher.
Stocks · News reference
Top 3 Health Care Stocks That May Keep You Up At Night This Month
Thermo Fisher, Moderna and Agilent show overbought RSI readings above 70, warning momentum-focused investors of potential near-term weakness.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
TD Cowen Maintains Buy on Agilent Technologies, Raises Price Target to $196
TD Cowen analyst Dan Brennan maintains Agilent Technologies (NYSE:A) with a Buy and raises the price target from $180 to $196.
Morgan Stanley Maintains Overweight on Agilent Technologies, Raises Price Target to $190
Morgan Stanley analyst Kallum Titchmarsh maintains Agilent Technologies (NYSE:A) with a Overweight and raises the price target from $175 to $190.
Agilent Announces Deal To Acquire Digital Pathology Software Firm Proscia For $240M Cash, Up To $30M In Milestones
Nasdaq 100 Slides As Micron, SanDisk, CoreWeave Sink: Stock Market Today
The Nasdaq 100 fell 1.5% at midday Friday as memory chips and AI-debt names sold off, while Fed Chair Warsh declined to rule out an October hike after hot CPI and PPI. WTI held near $96, the 10-year yield hovered around 5.1%, gold bounced toward $4,200 and bitcoin traded near $81,300.
Meet the New Nasdaq-100 Stock That’s Crushing Nvidia, Micron, and Sandisk. Is It Too Late to Buy?
Moderna stock has surged over 600% in 2026, outperforming major AI stocks like Nvidia, Micron, and Sandisk, driven by progress in its oncology pipeline, particularly its personalized cancer vaccine candidate intismeran autogene. The stock now trades 61% above Wall Street's average price target of $122, and while the company shows promise as it transforms from a coronavirus vaccine company into a broader biotech player, the analyst recommends waiting for a pullback before buying.